Global Short-acting EPO Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Short-acting EPO Drugs Market Research Report 2024
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
According to Mr Accuracy reports’s new survey, global Short-acting EPO Drugs market is projected to reach US$ 13830 million in 2029, increasing from US$ 9180 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029.
Short-acting EPO drugs have a wide range of applications in the market, primarily used for treating anemia-related conditions such as anemia associated with chronic kidney disease and in the supportive treatment of leukemia patients. The market size is substantial and continues to grow, particularly in Asian and European regions. Sales have been on the rise, reflecting increasing patient demand and benefiting from ongoing advancements in medical technology. In the future, short-acting EPO drugs are poised for further development, potentially encompassing the treatment of more anemia-related conditions and expanding their market share through innovative therapies and market expansion efforts.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Short-acting EPO Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Anemia
Kidney Disorders
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Short-acting EPO Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Short-acting EPO Drugs market is projected to reach US$ 13830 million in 2029, increasing from US$ 9180 million in 2022, with the CAGR of 6.2% during the period of 2024 to 2029.
Short-acting EPO drugs have a wide range of applications in the market, primarily used for treating anemia-related conditions such as anemia associated with chronic kidney disease and in the supportive treatment of leukemia patients. The market size is substantial and continues to grow, particularly in Asian and European regions. Sales have been on the rise, reflecting increasing patient demand and benefiting from ongoing advancements in medical technology. In the future, short-acting EPO drugs are poised for further development, potentially encompassing the treatment of more anemia-related conditions and expanding their market share through innovative therapies and market expansion efforts.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Short-acting EPO Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Segment by Application
Anemia
Kidney Disorders
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Short-acting EPO Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
